CB Insights
Technology Market Intelligence
Technology Market Intelligence
Human Genome Sciences is a development stage company that was formed to develop and commercialize therapeutically enhanced proprietary biopharmaceuticals with the aim of offering significant reductions in dosage, injection frequency, side effects, an...Show all
Company (Acquired)
Phone:
14200 Shady Grove Road
Rockville, 20850
Maryland, United States
| Total Funding | Date of Last Funding | |
|---|---|---|
| Human Genome Sciences | $0M | Jul 17, 2012 |
| Keryx Biopharmaceuticals | $87M | Jun 28, 2018 |
| Aerie Pharmaceuticals | $138.2M | Jun 1, 2018 |
| See all 16 competitors | ||
| Per Week | Per Month | Per 6 Months | Per Year | |
|---|---|---|---|---|
| Rank | Login to see details | |||
| Page Views Per Million | Login to see details | |||
| Page Views Per User | Login to see details | |||
| Reach Per Million | Login to see details | |||
| Investor | Investor Type | Location | Participating Rounds |
|---|
| Title | Application Date | Patent Date | Status (Patent / Application) |
|---|---|---|---|
| Vascular endothelial growth factor 2 | May 15, 2014 | Aug 02, 2016 | Patent |
| Albumin fusion proteins | Aug 05, 2015 | Mar 29, 2016 | Patent |
| Albumin fusion proteins | Feb 02, 2015 | Dec 29, 2015 | Patent |
| Antibodies that immunospecifically bind to b lymphocyte stimulator protein | Jan 23, 2012 | Nov 17, 2015 | Patent |
| Methods and compositions for use in treatment of patients with autoantibody positive disease | Jun 06, 2008 | Oct 27, 2015 | Patent |
